Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta
| العنوان: | Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta |
|---|---|
| المؤلفون: | Joris van Drongelen, Gaby A M Eliesen, Petra H.H. van den Broek, Annick de Vries, Nel Roeleveld, Nina I Kooijman, Frans G. M. Russel, Rick Greupink, Hedwig van Hove |
| المصدر: | Clinical Pharmacology and Therapeutics Clinical Pharmacology and Therapeutics, 108, 1, pp. 99-106 Clinical Pharmacology and Therapeutics, 108, 99-106 |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | musculoskeletal diseases, Adult, Placenta, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Pharmacology, 030226 pharmacology & pharmacy, Article, Etanercept, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, In vivo, immune system diseases, Pregnancy, Medicine, Humans, Pharmacology (medical), skin and connective tissue diseases, Maternal-Fetal Exchange, Retrospective Studies, Fetus, business.industry, Research, Infant, Newborn, Articles, Fetal Blood, Infliximab, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Pregnancy Complications, stomatognathic diseases, medicine.anatomical_structure, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], 030220 oncology & carcinogenesis, Cord blood, Tumor necrosis factor alpha, Female, Tumor Necrosis Factor Inhibitors, business, Ex vivo, medicine.drug |
| الوصف: | Contains fulltext : 220609.pdf (Publisher’s version ) (Open Access) Tumor necrosis factor (TNF) inhibitors are increasingly applied during pregnancy without clear knowledge of the impact on placenta and fetus. We assessed placental transfer and exposure to infliximab (n = 3) and etanercept (n = 3) in women with autoimmune diseases. Furthermore, we perfused healthy term placentas for 6 hours with 100 µg/mL infliximab (n = 4) or etanercept (n = 5). In pregnant women, infliximab transferred into cord blood but also entered the placenta (cord-to-maternal ratio of 1.6 ± 0.4, placenta-to-maternal ratio of 0.3 ± 0.1, n = 3). For etanercept, a cord-to-maternal ratio of 0.04 and placenta-to-maternal ratio of 0.03 was observed in one patient only. In ex vivo placenta perfusions, the extent of placental transfer did not differ between the drugs. Final concentrations in the fetal compartment for infliximab and etanercept were 0.3 ± 0.3 and 0.2 ± 0.2 µg/mL, respectively. However, in placental tissue, infliximab levels exceeded those of etanercept (19 ± 6 vs. 1 ± 3 µg/g, P |
| وصف الملف: | application/pdf |
| تدمد: | 0009-9236 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76edf0c9376283d1c6575724232f27a8 https://doi.org/10.1002/cpt.1827 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....76edf0c9376283d1c6575724232f27a8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00099236 |
|---|